{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    9,
    10,
    11,
    12,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "2",
        "name": "Amendment 2",
        "scope": {
          "id": "0eecd757-aa2d-4337-9f59-5c1d135611da",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "d8f62323-454d-45ca-b2f6-b01eb4c4588f",
          "code": {
            "id": "2e344c5e-0d01-4db4-9908-ff7e07672c30",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "c807b985-b749-4afc-a341-b1d603e08a30",
            "type": {
              "id": "22631e30-4346-4d0f-9720-e5de3cf41eb5",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The main purpose of this amendment is to implement the Urgent Safety Measures (USM) described in the 10-Aug-2021 Dear Investigator Letter (DIL) into the study protocol. The USM were implemented in response to the identification of a causal immune-mediated mechanism of the previously identified risk of retinal vasculitis (RV), and/or retinal vascular occlusion (RO), typically in the presence of intraocular inflammation (IOI) indicating a requirement to discontinue treatment in patients who develop events of RV and/or RO. This amendment also includes information on gender imbalance on IOI following brolucizumab treatment and recommendations on the time window for a study subject to receive the COVID-19 vaccine or vitrectomy.",
        "effectiveDate": "2021-09-28",
        "reasonIds": [
          "ar_1_1",
          "ar_1_2",
          "ar_1_3"
        ],
        "previousVersion": "01",
        "newVersion": "02"
      },
      {
        "id": "amend_2",
        "number": "1",
        "name": "Amendment 1",
        "scope": {
          "id": "87b2b2b1-cb12-42b7-b4d7-3b07ead1987b",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "dd7ff99d-c662-4e71-8352-026f7bbd4b1c",
          "code": {
            "id": "41378c71-31a7-4e17-87c0-d6293be56a48",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "9962e813-6a66-48b6-9160-0f858ffd60fd",
            "type": {
              "id": "47fd5130-a026-4d6e-8d91-60ee12b46e73",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The main purpose of this amendment is to provide clarification and guidance on safety assessments in accordance to the urgent safety measure regarding the post-marketing reports with brolucizumab (Beovu®) in the treatment of nAMD, which were identified as retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, that may result in severe vision loss. In addition, the amendment includes the modifications due to COVID-19 pandemic.",
        "effectiveDate": "2020-06-05",
        "reasonIds": [
          "ar_2_1",
          "ar_2_2",
          "ar_2_3"
        ],
        "previousVersion": "Original Protocol",
        "newVersion": "01"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_2",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_3",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_3",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [],
    "studySites": [],
    "summary": {
      "amendmentCount": 2,
      "countryCount": 0,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope"
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "2",
        "effectiveDate": "2021-09-28",
        "summary": "The main purpose of this amendment is to implement the Urgent Safety Measures (USM) described in the 10-Aug-2021 Dear Investigator Letter (DIL) into the study protocol. The USM were implemented in response to the identification of a causal immune-mediated mechanism of the previously identified risk of retinal vasculitis (RV), and/or retinal vascular occlusion (RO), typically in the presence of intraocular inflammation (IOI) indicating a requirement to discontinue treatment in patients who develop events of RV and/or RO. This amendment also includes information on gender imbalance on IOI following brolucizumab treatment and recommendations on the time window for a study subject to receive the COVID-19 vaccine or vitrectomy.",
        "previousVersion": "01",
        "newVersion": "02",
        "reasons": [
          "Safety",
          "Regulatory",
          "Administrative"
        ]
      },
      {
        "number": "1",
        "effectiveDate": "2020-06-05",
        "summary": "The main purpose of this amendment is to provide clarification and guidance on safety assessments in accordance to the urgent safety measure regarding the post-marketing reports with brolucizumab (Beovu®) in the treatment of nAMD, which were identified as retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, that may result in severe vision loss. In addition, the amendment includes the modifications due to COVID-19 pandemic.",
        "previousVersion": "Original Protocol",
        "newVersion": "01",
        "reasons": [
          "Safety",
          "Operational",
          "Scientific"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [],
      "regions": [],
      "plannedSites": null
    },
    "sites": []
  }
}